Monoclonal Antibody to Interleukin 33 (IL33)
| Code | Size | Price |
|---|
| MAB980Ra23-20ul | 20ul | £94.00 |
Quantity:
| MAB980Ra23-100ul | 100ul | £179.00 |
Quantity:
| MAB980Ra23-200ul | 200ul | £242.00 |
Quantity:
| MAB980Ra23-1ml | 1ml | £560.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
DV27; C9ORF26; IL1F11; NFHEV; Interleukin-1 Family, Member 11; Nuclear factor from high endothelial venules
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG2a Kappa
Immunogen:
RPB980Ra01-Recombinant Interleukin 33 (IL33)
Item Name:
Interleukin 33
Potency (Clone Number):
C5
Reactivity:
Hu;
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Interleukin 33 (IL33) | RPB980Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||